Anti-HTLV III ELISA and western blot testing in a blood donor population: implications for donor notificationKLEINMAN, S; ANTON-GUIRGIS, H; DWIGHT CULVER, B et al.Vox sanguinis (Basel. 1956). 1986, Vol 51, Num 2, pp 143-147, issn 0042-9007Article

Serial transmission of human T-cell leukemia virus type I by blood transfusion in rabbits and its prevention by use of X-irradiated stored bloodKOTANI, S; YOSHIMOTO, S; YAMATO, K et al.International journal of cancer. 1986, Vol 37, Num 6, pp 843-847, issn 0020-7136Article

Decision analysis of the HTLV-III screening test for blood donorsELLWEIN, L. B; PURTILO, D. T; PURTILO, R. B et al.AIDS research. 1986, Vol 2, Num 1, pp 5-17, issn 0737-6006Article

Disinfection and inactivation of the human T lymphotropic virus type III/lymphadenopathy-associated virusMARTIN, L. S; MCDOUGAL, J. S; LOSKOSKI, S. L et al.The Journal of infectious diseases. 1985, Vol 152, Num 2, pp 400-403, issn 0022-1899Article

Symposium on HTLV, december 6-7, 1984 Bethesda MDBRODER, S.Cancer research (Baltimore). 1985, Vol 45, Num 9, issn 0008-5472, 191 p.Conference Proceedings

Characterization of gp41 As the transmembrane protein coded by the HTLV-III/LAV envelope geneDI MARZO VERONESE, F; DE VICO, A. L; COPELAND, T. D et al.Science (Washington, D.C.). 1985, Vol 229, Num 4720, pp 1402-1405, issn 0036-8075Article

Inhibition of HTLV-III/LAV replication by foscarnetSARIN, P. S; TAGUCHI, Y; SUN, D et al.Biochemical pharmacology. 1985, Vol 34, Num 22, pp 4075-4079, issn 0006-2952Article

Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infectionCOLLINS, J. M; KLECKER, R. W; YARCHOAN, R et al.Journal of clinical pharmacology. 1986, Vol 26, Num 1, pp 22-26, issn 0091-2700Article

Performance evaluation of the Abbott HTLV III EIA, a test for antibody to HTLV III in donor bloodBARRETT, J. E; DAWSON, G; HELLER, J et al.American journal of clinical pathology. 1986, Vol 86, Num 2, pp 180-185, issn 0002-9173Article

Results of nationwide screening of blood and plasma for antibodies to human T-cell lymphotrophic III virus, type IIIKURITSKY, J. N; RASTOGI, S. C; FAICH, G. A et al.Transfusion (Philadelphia, PA). 1986, Vol 26, Num 2, pp 205-207, issn 0041-1132Article

Viral envelope protein of HTLV-III is the major target antigen for antibodies in hemophiliac patientsKITCHEN, L; MALONE, G; MARTINOWITZ, U et al.The Journal of infectious diseases. 1986, Vol 153, Num 4, pp 788-790, issn 0022-1899Article

Etiologie et immunopathologie du SIDA = Etiology and immunopathology of AIDSLANTIN, J.-P; FREI, P. C.Médecine et hygiène. 1986, Vol 44, Num 1655, pp 1273-1281, issn 0025-6749Article

Effect of heat and fresh human serum on the infectivity of human T-cell lymphotropic virus type III evaluated with new bioassay systemsHARADA, S; YOSHIYAMA, H; YAMAMOTO, N et al.Journal of clinical microbiology (Print). 1985, Vol 22, Num 6, pp 908-911, issn 0095-1137Article

The trans-activator gene of HTLV-III is essential for virus replicationFISHER, A. G; FEINBERG, M. B; WONG-STAAL et al.Nature (London). 1986, Vol 320, Num 6060, pp 367-371, issn 0028-0836Article

Spectrum of human T-cell lymphotropic virus type III infection in children: recognition of symptomatic, asymptomatic, and seronegative patientsSAVITA PAHWA; KAPLAN, M; FIKRIG, S et al.JAMA, the journal of the American Medical Association. 1986, Vol 255, Num 17, pp 2299-2305, issn 0098-7484Article

Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirusWILLEY, R. L; RUTLEDGE, R. A; DIAS, S et al.Proceedings of the National Academy of Sciences of the United States of America. 1986, Vol 83, Num 14, pp 5038-5042, issn 0027-8424Article

Aspects cliniques de l'infection par le virus LAV/HTLV-III = Clinical aspects of LAV/HTLV-III virus infectionROZENBAUM, W; GHARAKHANIAN, S.Concours médical (Paris). 1986, Vol 108, Num 25, pp 2113-2116, issn 0010-5309Article

HTLV-III serology in hemophilia: relationship with immunologic abnormalitiesGILL, J. C; MENITOVE, J. E; ANDERSON, P. R et al.The Journal of pediatrics. 1986, Vol 108, Num 4, pp 511-516, issn 0022-3476Article

Prevalence of human T-lymphotropic virus type III antibodies among patients in dialysis programs at a University HospitalMORRISON, A. J. JR; FREER, C. V; LYNN POOLE, C et al.Annals of internal medicine. 1986, Vol 104, Num 6, pp 805-807, issn 0003-4819Article

Defective postbinding lysis underlies the impaired natural killer activityin factor VIII-treated, human T lymphotropic virus type III seropositive hemophiliacsKATZMAN, M; LEDERMAN, M. M.The Journal of clinical investigation. 1986, Vol 77, Num 4, pp 1057-1062, issn 0021-9738Article

Natural killer cell activity from hemophiliacs exhibits differential responses to various forms of interferonMATHESON, D. S; GREEN, B. J; MAN-CHIU POON et al.Blood. 1986, Vol 67, Num 1, pp 164-167, issn 0006-4971Article

Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factorMCDOUGAL, J. S; MARTIN, L. S; CORT, S. P et al.The Journal of clinical investigation. 1985, Vol 76, Num 2, pp 875-877, issn 0021-9738Article

Safer blood supply against HTLV-IIIClinical pediatrics. 1986, Vol 25, Num 4, issn 0009-9228, 212Article

Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivoBRODER, S; COLLINS, J. M; MITSUYA, H et al.Lancet (British edition). 1985, Vol 2, Num 8456, pp 627-630, issn 0140-6736Article

Prospects of therapy for infections with human T-lymphotropic virus type IIIHIRSCH, M. S; KAPLAN, J. C.Annals of internal medicine. 1985, Vol 103, Num 5, pp 750-755, issn 0003-4819Article